Perspective Therapeutics Inc CATX

$2.76 +0.04 (1.47%)

Valuation

Market cap
310,493,000
Revenue TTM
$880,000
Net income TTM
$-103,120,000
PE ratio
0.00
Forward PE
—
Profit margin
-11,718.18%
Debt to equity
0.00

Trading

Volume
2,622,100
Avg volume
1,584,042
Day's range
$2.69 – $2.82
Shares out
114,152,000
Stochastic %K
55%
Beta
1.84
Analysts
Strong Sell
Price target
$12.29

Price

Company profile

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previous...

Show more

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.

Industry
Medical Devices
Sector
Healthcare
Phone
206 676 0900
Website
https://www.perspectivetherapeutics.com
Address
2401 Elliott Avenue, Suite 320, Seattle, United States

Latest news

Stocktwits

RadioIsotope25 Oct 3, 5:51 PM
$CATX https://finance.biggo.com/news/81d7c66efb9cc2e9
0 replies
RadioIsotope25 Oct 3, 1:44 PM
Shorts are getting burned in $IOVA while they are still short 87.9 million shares and the stock is up 421% YTD. Of all the biotechs with 20 million or more shares short $CATX is only one presenting data in Oct and Nov. stock is trading at Cash+ Real Estate value. https://www.sec.gov/Archives/edgar/data/728387/000119312526410663/catx-ex99_1.htm $OVID $VKTX
0 replies
Miura1957 Oct 3, 12:50 AM
$CATX looks like VMT01 is back in play…after initial mediocre readouts, looks like they hav found something worthy to present…now you can get 3 assets (1 on verge of Phase 3), production facilities, $200M cash…all for under $300M…seems like a steal
0 replies
Xanderzzzzzzz Oct 3, 12:10 AM
$CATX .................
0 replies
RadioIsotope25 Oct 2, 10:20 PM
$CATX https://nuclionews.com/article/orano-med-opens-europes-first-industrial-lead-212-radiopharma-plant-as-alpha-therapy-buildout-moves-to-scale
0 replies
rughead64 Oct 2, 7:57 PM
$CATX lets see what the close gives us
0 replies
Afterdark_HH Oct 2, 7:35 PM
$CATX so, they will present data at 3 conferences in October and November ? 😳🍀🍾👍🏻
0 replies
focafoca99 Oct 2, 7:23 PM
$CATX presents its [212Pb]VMT01 melanoma data at the SITC 2026 conference in November.
0 replies